Europe Bioproduction Market Forecast to 2030
Europe Bioproduction Market Forecast to 2030 – Regional Analysis – by Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), and End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others)
$2,840 – $4,440
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Prevalence of Chronic Diseases Drives Europe Bioproduction Market
Cardiovascular diseases (CVDs), neurological disorders, autoimmune disorders, and cancer are among the chronic diseases causing death and disabilities at a significant rate worldwide. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is also among the leading causes of mortality worldwide, affecting a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2020, ~10 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis’ Kymriah is used to treat diffuse large B-cell lymphoma.
Moreover, recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve life of millions of patients while saving billions of dollars of the healthcare system per year. They are effective and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases such as Crohn’s disease, psoriasis, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis.
As the prevalence of chronic diseases is increasing at a high rate, the demand for bioproduction in treating life-threatening illnesses has progressed rapidly over the last five years, thereby driving the bioproduction market.
Europe Bioproduction Market Overview
The Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global bioproduction market and is estimated to register a notable CAGR during 2022-2030. The increasing prevalence of chronic disorders has resulted in a growing number of product launches and approvals, along with technological advancements and investment, thereby contributing to the market growth in the region.
Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare industry. Healthcare professionals can treat more patients with high-quality biologics at reduced cost. Due to the massive potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As a few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. In addition, healthcare providers such as PHI Orthopedic Physiotherapy Center, German International Clinic, Frankfurt, Germany; CBC Health Munich, Germany; and other providers offer stem cell therapy for various chronic diseases such as diabetic retinopathy, optic nerve neuritis, and rheumatoid arthritis. This is expected to increase the adoption of cell therapies in the coming years. Also, a growing number of partnerships among international players boost the market growth. For instance, in November 2020, Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including expanded commercial drug product manufacturing capacity in Europe for ZYNTEGLO, a one-time gene therapy for transfusion-dependent β-thalassemia (TDT). Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to flourish.
Europe Bioproduction Market Revenue and Forecast to 2030 (US$ Million)
Europe Bioproduction Market Segmentation
The Europe bioproduction market is categorized into product, application, equipment, end user, and country.
Based on product, the Europe bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest Europe bioproduction market share in 2022.
In terms of application, the Europe bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest Europe bioproduction market share in 2022.
By equipment, the Europe bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest Europe bioproduction market share in 2022.
In terms of end user, the Europe bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest Europe bioproduction market share in 2022.
By country, the Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe bioproduction market share in 2022.
Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the Europe bioproduction market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Europe bioproduction market was valued at US$ 5,515.06 million in 2022 and is expected to reach US$ 14,789.80 million by 2030, registering a CAGR of 13.1% from 2022 to 2030. Patent expiry of blockbuster biologics and increasing prevalence of chronic diseases are among the critical factors attributed to drive the Europe bioproduction market growth.
Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. Patents on originator biologicals are expected to expire in the coming years.
Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table.
Biologicals Expiry Dates
Avastin January 2022
Cyramza May 2023
Adcetris August 2023
Abthrax October 2024
Gazyva/Gazyvaro November 2024
Darzalex May 2026
Ocrevus April 2027
Emgality September 2028
Hemlibra February 2028
Llumetri March 2028
Imfinzi September 2028
Mylotarg April 2028
Imfinzi September 2028
Mylotarg April 2028
Sylvant July 2034
The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the bioproduction market during the forecast period.
On the contrary, high cost of cell therapy and biosimilar manufacturing hampers the growth of Europe bioproduction market.
Based on product, the Europe bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held 38.2% Europe bioproduction market share in 2022, amassing US$ 2,106.27 million. It is projected to garner US$ 5,293.82 million by 2030 to register 12.2% CAGR during 2022-2030.
In terms of application, the Europe bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held 37.3% share of Europe bioproduction market in 2022, amassing US$ 2,056.56 million. It is anticipated to garner US$ 5,737.88 million by 2030 to expand at 13.7% CAGR during 2022-2030.
By equipment, the Europe bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held 39.3% share of Europe bioproduction market in 2022, amassing US$ 2,166.92 million. It is projected to garner US$ 6,142.60 million by 2030 to expand at 13.9% CAGR from 2022 to 2030.
In terms of end user, the Europe bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held 52.8% share of Europe bioproduction market in 2022, amassing US$ 2,910.54 million. It is projected to garner US$ 7,720.31 million by 2030 to expand at 13.0% CAGR from 2022 to 2030.
Based on country, the Europe bioproduction market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 27.0% share of Europe bioproduction market in 2022. It was assessed at US$ 1,486.31 million in 2022 and is likely to hit US$ 4,175.16 million by 2030, registering a CAGR of 13.8% during 2022-2030.
Key players operating in the Europe bioproduction market are Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc., among others.
In March 2023, Lonza declared that its intended cGMP clinical and commercial drug product production line in Visp (CH) has been completed. Customers with a range of production demands for drug products, for both clinical and commercial supply, will be served by the new line. Modern liquid and lyophilized vial filling isolator line for multiple modalities that satisfies the GMP Annex 1 requirement for the manufacture of sterile products is part of this 1,200 square metre cGMP facility1. The line is already completely operating and has a cGMP license; in April 2023, the first client batches are scheduled to be filled.
In October 2023, Lonza announced the expansion of a partnership for the commercial-scale filling of ADCs with a significant biopharmaceutical partner. At its Stein (CH) facility, Lonza is required under the agreement to build a specialized aseptic cGMP filling line on a commercial scale. The aseptic filling of highly potent ADCs and containment lyophilization will be made possible by the new dedicated filling line. The extra filling capabilities bolster Lonza’s ability and adaptability to support the commercial and clinical supply of bioconjugates even more.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Europe bioproduction market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe bioproduction market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Bioproduction Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Rising Adoption of Regenerative Medicines
4.1.2 Increasing Prevalence of Chronic Diseases
4.2 Market Restraints
4.2.1 High Cost of Cell Therapy and Biosimilar Manufacturing
4.3 Market Opportunities
4.3.1 Patent Expiry of Blockbuster Biologics
4.4 Future Trends
4.4.1 Shift Toward Automated Cell Therapy Manufacturing
4.5 Impact Analysis
5. Bioproduction Market – Europe Market Analysis
5.1 Europe Bioproduction Market Revenue (US$ Mn), 2020 – 2030
6. Europe Bioproduction Market – Revenue and Forecast to 2030 – by Product
6.1 Overview
6.2 Europe Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
6.3 Biologics and Biosimilars
6.3.1 Overview
6.3.2 Biologics and Biosimilars: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Cell and Gene Therapies
6.5.1 Overview
6.5.2 Cell and Gene Therapies: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Nucleic Acid Therapeutics
6.6.1 Overview
6.6.2 Nucleic Acid Therapeutics: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.7 Others
6.7.1 Overview
6.7.2 Others: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7. Europe Bioproduction Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 Europe Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Rheumatoid Arthritis
7.5.1 Overview
7.5.2 Rheumatoid Arthritis: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Hematological Disorders
7.6.1 Overview
7.6.2 Hematological Disorders: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Diabetes
7.7.1 Overview
7.7.2 Diabetes: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Bioproduction Market – Revenue and Forecast to 2030 – by Equipment
8.1 Overview
8.2 Europe Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
8.3 Consumables and Accessories
8.3.1 Overview
8.3.2 Consumables and Accessories: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Downstream Equipment
8.4.1 Overview
8.4.2 Downstream Equipment: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Bioreactors
8.5.1 Overview
8.5.2 Bioreactors: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5.2.1 Europe: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
8.6 Upstream Equipment
8.6.1 Overview
8.6.2 Upstream Equipment: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Bioproduction Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Europe Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Biopharmaceutical Companies
9.3.1 Overview
9.3.2 Biopharmaceutical Companies: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Contract Manufacturing Organizations
9.4.1 Overview
9.4.2 Contract Manufacturing Organizations: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10. Europe Bioproduction Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Europe: Bioproduction Market
10.1.1 Europe: Bioproduction Market, by Country, 2022 & 2030 (%)
10.1.1.1 Germany: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Germany: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.2 Germany: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.1.3 Germany: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.1.4 Germany: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.1.4.1 Germany: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.1.5 Germany: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.2 UK: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 UK: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 UK: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.2.4 UK: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.2.5 UK: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.2.5.1 UK: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.2.6 UK: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.3 France: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 France: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 France: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.3.4 France: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.3.5 France: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.3.5.1 France: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.3.6 France: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.4 Italy: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.3 Italy: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.4.4 Italy: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.4.5 Italy: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.4.5.1 Italy: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.4.6 Italy: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.5 Spain: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.3 Spain: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.5.4 Spain: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.5.5 Spain: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.5.5.1 Spain: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.5.6 Spain: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.6 Rest of Europe: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.3 Rest of Europe: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.6.4 Rest of Europe: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.6.5 Rest of Europe: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.6.5.1 Rest of Europe: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.6.6 Rest of Europe: Bioproduction Market, by End User, 2020-2030 (US$ Million)
11. Bioproduction Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Bioproduction Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 . Lonza Group AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 bbi-biotech GmbH
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Danaher Corp
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sartorius AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 FUJIFILM Irvine Scientific Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck KGaA
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 F. Hoffmann-La Roche Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Bio-Rad Laboratories Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
LIST OF TABLES
Table 2. Europe Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 3. Germany Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 4. Germany Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. Germany Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 6. Germany Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 8. UK Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 9. UK Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 10. UK Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 11. UK Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 12. UK Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. France Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. France Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 15. France Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 16. France Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 17. France Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 20. Italy Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 21. Italy Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 22. Italy Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 23. Spain Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 24. Spain Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 25. Spain Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 26. Spain Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 27. Spain Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 28. Rest of Europe Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Europe Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Europe Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Europe Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Europe Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 33. Recent Inorganic Growth Strategies in the Bioproduction Market
Table 34. Recent Organic Growth Strategies in the Bioproduction Market
Table 35. Glossary of Terms, Bioproduction Market
LIST OF FIGURES
Figure 2. Europe Bioproduction Market: Key Industry Dynamics
Figure 3. Europe Bioproduction Market: Impact Analysis of Drivers and Restraints
Figure 4. Europe Bioproduction Market Revenue (US$ Mn), 2020 – 2030
Figure 5. Europe Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
Figure 6. Biologics and Biosimilars: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Vaccines: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Cell and Gene Therapies: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Nucleic Acid Therapeutics: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
Figure 12. Cancer: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Cardiovascular Diseases: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Rheumatoid Arthritis: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Hematological Disorders: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Diabetes: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
Figure 19. Consumables and Accessories: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Downstream Equipment: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Bioreactors: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Upstream Equipment: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Europe Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
Figure 24. Biopharmaceutical Companies: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Contract Manufacturing Organizations: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Others: Europe Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Europe: Bioproduction Market, by Key Country – Revenue (2022) (US$ Million)
Figure 28. Europe: Bioproduction Market, by Country, 2022 & 2030 (%)
Figure 29. Germany: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. UK: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. France: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Italy: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Spain: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Rest of Europe: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Growth Strategies in the Bioproduction Market
1. bbi-biotech GmbH
2. Bio-Rad Laboratories Inc
3. Danaher Corp
4. F. Hoffmann-La Roche Ltd
5. FUJIFILM Irvine Scientific Inc
6. Lonza Group AG
7. Merck KGaA
8. Sartorius AG
9. Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.